Podcasts about Cart

Taken as a group, blood cancers are the fifth most common type of cancer in New Zealand - affecting around one in twenty people during their lifetime. But some patients are forced to seek help overseas because a treatment that could save them isn't available here. The Wellington based Malaghan Institute of Medical Research is working to change that. Winner of this year's Breakthrough Project category in the KiwiNet Awards, Malaghan is currently conducting phase two of its CAR-T cell therapy clinical trials. The therapy essentially uses the body's own immune system to target and kill cancer cells. Professor Robert Weinkove is the Clinical Director and he speaks to Mihi about the next major step in their push to make it a standard part of cancer care in New Zealand.

Aaron & Tom review the state of the holiday retail climate, the history of America's vapor economics, the CNN x Kalshi collab, and financing Air Jordans at 22% interest. Subscribe to our patreon today: https://www.patreon.com/trillbillyworkersparty

Live from the Amazon Warehouse in Robbinsville, in this episode of The Speed of Culture podcast, Matt Britton speaks with Amanda Doerr, Vice President of Core Shopping at Amazon, for a deep and practical look at how Amazon AI shopping is reshaping the entire buying journey. From the launch of Rufus AI shopping assistant and breakthroughs in AI review summarization to the rise of conversational commerce, voice commerce, and mobile-first e-commerce, Amanda shares how Amazon is solving customer friction and building the foundation for the future of e-commerce 2026.Follow Suzy on Twitter: @AskSuzyBizFollow Amanda Doerr on LinkedInSubscribe to The Speed of Culture on your favorite podcast platform.And if you have a question or suggestions for the show, send us an email at suzy@suzy.com Hosted on Acast. See acast.com/privacy for more information.

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS.  In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to fight a particular condition. This receptor is known as a chimeric antigen receptor, or CAR. Over several weeks in the lab, these fortified T-cells multiply until there are millions of them, then they're reintroduced to the patient by intravenous infusion. CAR-T cell therapy is already used to treat some blood cancers, and Jan is the first person in the world to receive this one-and-done treatment to treat MS. She's joining us to share her experience participating in the clinical trial and to give us an update on how she's doing following her treatment.  This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct4 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

Drs. Danilov and Coombs review the evolving treatment strategies for CLL, focusing on the use of CAR T-cell therapy and allogeneic stem cell transplant in different disease stages, particularly for patients with relapsed or refractory disease. They emphasize the importance of tailoring treatment to individual patient needs, considering clinical trials, and recognizing challenges.

Featuring an interview with Dr Matthew Lunning, including the following topics: Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00) Overview of the CAR T-cell therapy administration process (4:40) Opportunities for referral for CAR T-cell therapy (10:05) Selection of a CAR T-cell therapy based on patient characteristics (16:09) Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23) Safety regulations and mitigation strategies for adverse events (30:36) Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16) Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09) Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09) CME information and select publications

Featuring a slide presentation and related discussion from Dr Matthew Lunning, including the following topics: Overview of available chimeric antigen receptor (CAR) T-cell therapies (0:00) Toxicities associated with CAR T-cell therapy (4:03) Mitigation strategies for adverse events (22:02) Novel strategies for outpatient infusion (26:34) Changes to the CAR T-cell therapy safety regulations (30:23) CME information and select publications

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

 In this week's episode, Blood editor Dr. James Griffin speaks with Drs. Emanuele Zucca and Sandra Pinho about their latest articles published in Blood. Dr. Zucca discusses his second analysis of the IELSG37 trial, where findings suggested that R-CHOP21 rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone, administered every 21 days) may be a suboptimal frontline regimen for PMBCL. Dr. Pinho discusses the aging megakaryocytic niche and its influence on the age-associated decline in HSC and progenitor cell function. The authors demonstrate that remodeling of the megakaryocytic niche and associated platelet factor 4 (PF4) downregulation are central mechanisms driving HSC aging.Featured Articles: Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging 

Drew Ann Long's journey also underscores the complex realities faced by female entrepreneurs and mothers as they navigate the challenging waters of corporate America, especially within traditionally male-dominated spheres. Confronted by skepticism and bias, Drew Ann relied on a blend of strategic preparation and personal conviction, ensuring her rights and her invention's mission remained protected at every step. Her resilience and ability to balance the demands of business leadership and caregiving highlight the multifaceted nature of her success, demonstrating that enduring perseverance and emotional intelligence are as critical as any business skill. Her work with Caroline's Cart marks more than business accomplishment—it represents a larger cultural transformation toward recognizing and valuing the differently-abled community and their families. Through persistent advocacy and an unwavering mission for inclusion, Drew Ann has compelled major retailers to address a demographic previously overlooked in both product development and customer service. Additionally, with the founding of Caroline's Cause, she extends her impact even further, supporting not just those with special needs but the siblings whose contributions are often quietly heroic. Motivated by her remarkable story and commitment, Drew Ann Long encourages you to be part of the movement for greater accessibility, inclusion, and resilience. To learn more about her journey, speaking engagements, and ongoing advocacy, visit her website here. For the accessible version of the podcast, go to our Ziotag gallery.We're happy you're here! Like the pod?Support the podcast and receive discounts from our sponsors: https://yourbrandamplified.codeadx.me/Leave a rating and review on your favorite platformFollow @yourbrandamplified on the socialsTalk to my digital avatar Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Danilov and Coombs explore the potential benefits and challenges of CAR T-cell therapy in CLL, emphasizing the importance of personalized treatment decisions and shared decision-making between physicians and patients.

Ashlee finds out some information she wishes she never knew about her dadSee omnystudio.com/listener for privacy information.

Many see Amazon as a reliable source of consumer goods from toilet paper to wireless headphones. But Sean McLain reports that the “everything store” is now betting that consumers will also pick up much bigger items when given the opportunity. Plus, Imani Moise reports on why fintech company Block is sharing its version of a credit store with customers. Patrick Coffee hosts. Sign up for the WSJ's free Technology newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's Tarp Find mini-episode is a heartwarming story about Penn State football player Vega Ioane pitching in to lend a helping hand off the field. Programming Note: Nothing is changing with Andrew's weekly interview episodes. Andrew's interview episodes will continue to be in your podcast feed every Thursday morning again once Season 14 launches on January 8th.

A MoDot engineer joins Chris and Amy to explain what happened to snow removal yesterday; Amy wants to ride the giant Schnucks shopping cart; Sean Malone shares the story of one truck driver shooting another on I-55; Blues netminder Jordan Binnington was angry after being pulled last nite.

God is asking you to follow him in a way that will require your faith. You're not going to understand it. You're not going to be in control of it. Can your mind make peace with the unknown? Can your hands remain open in full surrender? And girl, will your feet move forward to destination […]

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

In today's Tech3 from Moneycontrol, we break down Myntra's next wave of global expansion, LTIMindtree's decision to halt new H-1B filings, and Skyroot's warning on the global small-rocket shortage. We also discuss the government's directive to preinstall the Sanchar Saathi cybersecurity app on all smartphones and why influencers are still struggling to adapt to new AI-labelling rules

PIX bate recorde e registra 297,4 milhões de operações em um dia. Metrô de SP passa a aceitar cartão de crédito e débito na catraca. Vídeos revelam táticas para expulsar pessoas em situação de rua. Quarto privativo, cama e TV de 32": como é o avião que fará voo mais longo do mundo. Como atravessar o pós-derrota do Palmeiras sem abalar a saúde mental.

Este jueves a las 12:00, el IES Terra de Trasancos de Narón estrenará su alumbrado navideño acompañado de un original poblado realizado por los alumnos reciclando cajas de cartón. La iniciativa, impulsada por los estudiantes de primero y cuarto de ESO junto con el Club de Ciencia del centro, busca fomentar la creatividad, el trabajo colaborativo y la sostenibilidad, transformando materiales reciclados en un Belén y un pequeño pueblo navideño lleno de detalles. El acto de inauguración contará con una fiesta especial y la actuación del coro Solidarium, generando un ambiente festivo y luminoso similar al de grandes ciudades. Además, ese día se entregarán los premios del concurso de diseño del logo de la radio escolar Ourizo FM, que permitirá a los alumnos participar activamente en la comunicación y expresión oral mediante programas de radio y podcasts. El poblado y la iluminación estarán abiertos al público durante el horario lectivo del instituto, invitando a familias y visitantes de Narón, Ferrol y alrededores a disfrutar del trabajo de los alumnos y del espíritu navideño que inunda el centro educativo.

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Os passageiros do Metrô agora podem pagar a tarifa diretamente em catracas exclusivas das estações, utilizando cartões físicos de débito e crédito com tecnologia de aproximação. A iniciativa faz parte de um novo projeto piloto, iniciado nesta segunda-feira (1), com duração inicial de seis meses e possibilidade de prorrogação, que busca avaliar a aceitação dos passageiros e ajustes que possam ser feitos.

Hablamos de traumatología con los mejores especialistas de la Clínica CEMTRO, referente absoluto en cirugía traumatológica deportiva además centro médico de excelencia FIFA. La Dra. Isabel Guillén es traumatóloga experta en cirugía de pie, tobillo y patologías del cartílago articular. Jefa de la Unidad de Cartílago en Clínica CEMTRO, forma también parte del equipo de la Unidad de Rodilla, Unidad de Pie y Tobillo, y también de CEMTRO Premium. Su trayectoria está centrada en el tratamiento de condropatías, osteocondritis disecante y artrosis. See omnystudio.com/listener for privacy information.

Hablamos de traumatología con los mejores especialistas de la Clínica CEMTRO, referente absoluto en cirugía traumatológica deportiva además centro médico de excelencia FIFA. La Dra. Isabel Guillén es traumatóloga experta en cirugía de pie, tobillo y patologías del cartílago articular. Jefa de la Unidad de Cartílago en Clínica CEMTRO, forma también parte del equipo de la Unidad de Rodilla, Unidad de Pie y Tobillo, y también de CEMTRO Premium. Su trayectoria está centrada en el tratamiento de condropatías, osteocondritis disecante y artrosis. See omnystudio.com/listener for privacy information.

O áudio-árbitro Pedro Henriques considera que ficou por mostrar um cartão amarelo a Boma, William Gomes e ainda Ferro. Nota 6. "Árbitro acertou no essencial. Gestão disciplinar foi regular".See omnystudio.com/listener for privacy information.

00:00 O contrato de pobreza que você assinou01:08 Item 01 - O erro clássico que cria a bola de neve02:45 Item 02 - Queimando dinheiro (literalmente)04:02 Item 03 - A morte por mil cortes05:34 Item 04 - O trapo de ouro (Cuidado com isso!)06:59 RC Club09:17 Item 05 - O recado para os marombas11:14 Item 06 - Noite de rei, vida de plebeu12:38 Item 07 - A ilusão de ótica que dói no ego 14:39 RC Wealth

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

Santa, baby! We're here to deliver the #damngood gifts of the season that the beauty lover on your list will *actually* want - no snoozefest presents in sight. Watch, and subscribe to this episode on YouTube! You'll hear about:The makeup musts we're swooning over (a luxury blush trio, lip gloss “stacks,” and a palette fit for Celine Dion)A makeup-meets-indie jewellery collab that's sure to spark conversation at any holiday party A chic AF bar soap gift set that's giving us major flashbacks to a coveted childhood stocking stufferThe high quality hair clips that not only hold up the thickest hair, but that are also the hottest style accessory of the season A French-girl approved advent calendar that doesn't skimp out on beauty goodiesA limited edition version of a 100-year old fragrance that's been updated for the vanilla lover on your list! (And the insider tip for how you can personalize it.) One of the most-searched for beauty gifts of the season, revealed (this one might surprise you!) Get social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/ Related episodes like this: Shop Smarter, Not Harder – How-to Get Real Value from Your Beauty Buys

Send us a textWe explore how clear data, simple habits, and dietitian guidance can cut through grocery aisle confusion and help people make faster, healthier choices. Galen from GreenChoice shares new findings on ultra-processed foods, why retailers matter, and how personalization empowers every shopper.• founding spark in the egg aisle and the problem with label claims• upbringing, athletics and the path to building transparent food data• how the GreenChoice score and app work across four health pillars• support for allergies, celiac disease and diabetes through filters• sobering stats on highly processed foods by category and retailer• shopper trends toward fewer additives and more ingredient clarity• a three-step label reading method that saves time• the role of dietitians, personalization and shelf-level tools• AI, wearables and the future of real-time nutrition guidance• community and family dynamics that make change stick• practical staples and what's next for GreenChoiceGo check it out. It's an incredible resource for anyone who wants to eat well and shop with confidence. Thank you for listening. Please subscribe to this podcast and share with a friend. If you would like to know more about my services, please message at fueledbyleo@gmail.comMy YouTube Channel https://www.youtube.com/channel/UC0SqBP44jMNYSzlcJjOKJdg

Invités :Général Emmanuel de Richoufftz, vice-président de Place d'armes.Gauthier Le Bret, journaliste.Eric Naulleau, journaliste.Louis de Raguenel, chef du service politique d'Europe 1.Sabrina Medjebeur, essayiste-sociologue.Eric Revel, éditorialiste politique.Marc Fiorentino, économiste. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Prosecutors allege that during a video-conference session with her lawyers at MDC Brooklyn, Maxwell used a large cart loaded with legal documents to block the door of a dedicated conference room, effectively preventing prison staff from entering. The filing states she was permitted to bring the cart into the video‐teleconference (VTC) room for meetings, but then “used that cart to barricade the door to the room” when staff attempted to gain access.In response, Maxwell's legal team denied the barricade claim, arguing the government was “gratuitously casting” her in a negative light to justify stricter limits on her legal material access. Following the incident, prison authorities removed and banned the use of the cart during her meetings, directing that she instead carry her documents by hand and make multiple trips if needed.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

This month, the gals bless us with their long-time bestie, the famous Blortney! Topics include guinea pig parties, overturned monkeys, a poopy pants puzzle, and eyebrow innovation. Don't be a stinker and a meanie, tune in for November's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.

CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient’s own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartnerSee omnystudio.com/listener for privacy information.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Episodio exclusivo para suscriptores de Se Habla Español en Apple Podcasts, Spotify, iVoox y Patreon: Spotify: https://open.spotify.com/show/2E2vhVqLNtiO2TyOjfK987 Patreon: https://www.patreon.com/sehablaespanol Buy me a coffee: https://www.buymeacoffee.com/sehablaespanol/w/6450 Donaciones: https://paypal.me/sehablaespanol Contacto: sehablaespanolpodcast@gmail.com Facebook: www.facebook.com/sehablaespanolpodcast Twitter: @espanolpodcast Hola, ¿cómo va todo? Aquí en Luxemburgo ya estamos viviendo el espíritu de la Navidad, porque este fin de semana han abierto los mercadillos navideños, concretamente el pasado viernes 21 de noviembre. Como en este país no se celebra la fiesta de los Reyes Magos, la Navidad termina el 1 de enero. Ya sabes que en España termina el día 6, aunque los estudiantes suelen tener libre incluso el 7 de enero. Y estas fechas son muy especiales para las familias que tienen a alguien enfermo, sobre todo si es un niño o un adolescente. A todas ellas, un abrazo muy fuerte desde aquí, y también una buena noticia que compartir. Porque hoy vamos a hablar de un tema muy importante: la lucha contra el cáncer y un nuevo tratamiento que está funcionando en España. Pero antes vamos a explicar algunas diferencias entre la sanidad pública y la sanidad privada en mi país. En España, la sanidad pública está financiada por los impuestos y las cotizaciones sociales. Esto significa que, si trabajas y cotizas, tienes acceso gratuito a médicos, hospitales y urgencias. Solo hay que pagar una parte de los medicamentos, lo que se llama copago. Por ejemplo, una persona con ingresos bajos puede pagar unos 8 euros por un medicamento que cuesta mucho más. Por otro lado, la sanidad privada funciona con seguros médicos. Las personas pagan una póliza mensual para tener acceso más rápido a especialistas, elegir médico o recibir servicios extra como atención dental o revisiones oftalmológicas, de la vista. Los precios varían: un joven puede pagar unos 20 o 30 euros al mes, mientras que una persona mayor puede pagar más de 100 euros mensuales. Muchas personas en España combinan ambos sistemas: usan la sanidad pública para lo esencial y contratan un seguro privado para evitar listas de espera o tener más comodidad. Con esta información como contexto, vamos a escuchar una noticia que nos habla de un avance médico realizado en un hospital público. Y es que el Hospital de La Paz, en Madrid, ha conseguido curar a varios niños con leucemia gracias a una terapia experimental. A lo largo del episodio, vamos a aprender vocabulario relacionado con este tema. Pero lo primero es escuchar la noticia, que pertenece una vez más a Radio Nacional de España. Presta mucha atención. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” La verdad es que da gusto escuchar noticias positivas relacionadas con el cáncer, porque es una enfermedad que termina con la vida de miles de personas cada año, y los avances médicos suelen tardar mucho tiempo en llegar. Pero bueno, de vez en cuando aparecen nuevos tratamientos que funcionan, como el que nos han contado en la noticia. Con respecto al vocabulario, no he encontrado mucho que explicar, pero vamos a reforzar algunos conocimientos para que estén todavía más claros. Terapia experimental: Tratamiento médico nuevo que aún está en fase de prueba y no se ha aprobado oficialmente para su uso general. Ejemplos: Los médicos aplicaron una terapia experimental para tratar el cáncer que no respondía a otros tratamientos. Aunque es una terapia experimental, ha mostrado resultados muy prometedores en algunos pacientes. Hacer vida normal: Volver a la rutina diaria habitual después de una enfermedad o situación difícil. Ejemplos: Después de la operación, pudo hacer vida normal y volver al trabajo. Lucía ha empezado a hacer vida normal tras superar la leucemia. Arropar: En sentido figurado, significa proteger, apoyar o dar cariño a alguien, especialmente en momentos difíciles. Ejemplos: Su familia lo arropó durante todo el tratamiento. En el colegio, los profesores y compañeros la están arropando mucho. Recaída: Cuando una persona vuelve a enfermar después de haber mejorado o superado una enfermedad. Ejemplos: Tras varios meses sin síntomas, tuvo una recaída y volvió al hospital. Las recaídas son comunes en enfermedades como la leucemia. Pasar desapercibida: No ser notado o detectado; en medicina, se refiere a células o síntomas que no se identifican fácilmente. Ejemplos: Las células cancerosas pueden pasar desapercibidas tras el primer tratamiento. Su talento no pasó desapercibido en el concurso de canto. Fijar: En medicina, significa unir o dirigir algo hacia un objetivo específico; también puede significar establecer o asegurar algo. Ejemplos: El tratamiento fija dos moléculas para atacar el cáncer sin dejarle escondite. Han fijado la fecha de la operación para el próximo lunes. Muy bien. Como te decía, el resto del vocabulario es bastante sencillo, y supongo que lo conoces perfectamente. Así que, escuchamos la noticia por segunda vez. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” Sé que lo tienes todo muy claro, pero ya sabes que me gusta ofrecerte la noticia cambiando algunas palabras para que puedas ampliar tu vocabulario. Y es lo que voy a hacer ahora mismo. La información se refiere al sistema médico público, en concreto el Hospital de La Paz en Madrid, porque ha conseguido devolverle la salud a ocho menores —niños y adolescentes— que padecían cáncer, una variante severa de leucemia, y que ya no contaban con ninguna alternativa de recuperación. Este logro ha sido posible gracias a un procedimiento innovador con células, y ahora estos jóvenes han vuelto a tener una rutina habitual. Una de ellas, Lucía, de 15 años, ha compartido su experiencia con Radio Nacional de España. Y gracias a este método terapéutico, tiene muchos proyectos para el futuro. En concreto, Lucía ha revelado tres cosas importantes: la primera, que desea estudiar Biología; la segunda, que en el colegio la están apoyando emocionalmente mucho; y la tercera, y más relevante, que está libre de la enfermedad. Dice que se encuentra fenomenal. Antes solía tener reapariciones de la enfermedad cada año, y bastante fuertes, pero esta vez no ha tenido ninguna, y está muy feliz porque parece que, por fin, está curada. Después de 15 años de batalla contra la leucemia y cuatro recaídas, Lucía ha comenzado a retomar su vida cotidiana. El tratamiento, conocido como CAR-T en combinación, se ha aplicado a diez pacientes que ya habían pasado por quimioterapia y por trasplantes para intentar detener el avance de la dolencia. Ocho de ellos ya están libres de cáncer. El gran desafío de la leucemia son las reapariciones, ya que las células malignas, tras el primer tratamiento, pueden camuflarse en ciertas moléculas para no ser detectadas y luego volver a atacar. Lo que hace este tratamiento es dirigirse simultáneamente a dos moléculas y dejar al cáncer sin posibilidad de esconderse. El resultado, como decíamos, ocho menores recuperados y una nueva ilusión para vencer definitivamente esta enfermedad. Por cierto, me gusta mucho el verbo “camuflarse”, que es como esconderse, pero utilizando alguna estrategia especial. Por ejemplo, podemos camuflarse con un disfraz para que nadie sepa quiénes somos. Venga, vamos a escuchar la noticia por última vez y te cuento más detalles sobre el impacto del cáncer en España. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” Como te decía, para concluir vamos a repasar las estadísticas más recientes sobre el cáncer infantil en España. En 2024 se registraron alrededor de 1.500 casos nuevos en niños menores de 14 años. Pero lo realmente alentador es el avance en las tasas de supervivencia. Según los últimos informes, la tasa de supervivencia a cinco años tras el diagnóstico se sitúa en un impresionante 83,9 % para menores de 0 a 14 años. Esta cifra refleja una mejora constante en comparación con décadas atrás; en los años ochenta y noventa la supervivencia estaba muy por debajo, entre el 60 % y el 70 %. Estos datos ponen en evidencia que la investigación médica y los avances terapéuticos han conseguido que hoy más del 80 % de los niños con cáncer logren superarlo. Se evidencia también que cuanto más tiempo pasa tras el diagnóstico —especialmente superados los cinco años— menor es el riesgo de recaída, gracias a programas de seguimiento sólido que permiten detectar y tratar a tiempo posibles complicaciones. Este progreso va de la mano de innovaciones como la terapia CAR‑T, de la que hemos hablado hoy, y de los múltiples esfuerzos en medicina personalizada y oncología pediátrica. El mensaje es claro: aunque cada año se diagnostican nuevos casos, las posibilidades de curación siguen mejorando, ofreciendo un horizonte mucho más esperanzador para niños y adolescentes afectados. Y ahora, como siempre, repasamos las palabras y expresiones que hemos explicado hoy. Terapia experimental: Tratamiento médico nuevo que aún está en fase de prueba y no se ha aprobado oficialmente para su uso general. Hacer vida normal: Volver a la rutina diaria habitual después de una enfermedad o situación difícil. Arropar: En sentido figurado, significa proteger, apoyar o dar cariño a alguien, especialmente en momentos difíciles. Recaída: Cuando una persona vuelve a enfermar después de haber mejorado o superado una enfermedad. Pasar desapercibida: No ser notado o detectado; en medicina, se refiere a células o síntomas que no se identifican fácilmente. Fijar: En medicina, significa unir o dirigir algo hacia un objetivo específico; también puede significar establecer o asegurar algo. Pues esto ha sido todo por hoy. Espero que la noticia te haya alegrado tanto como a mí, porque muchas veces sólo escuchamos malas noticias en los medios de comunicación. Ojalá encuentre más informaciones de este tipo en el futuro para poder hablar de ellas aquí. Mil gracias de nuevo por tu apoyo y hasta la próxima semana. Adiós. Escucha este episodio completo y accede a todo el contenido exclusivo de Se Habla Español. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/171214

Join hosts Eddie, Ashwin, and Raj as they welcome Dr. Michelle Yong and Dr. Gemma Reynolds, academic infectious diseases physicians from the Peter MacCallum Cancer Centre and the National Centre for Infections in Cancer, for an in-depth discussion on cytomegalovirus (CMV) management in immunocompromised hematology patients.Key Topics CoveredFundamentals of CMV ManagementDistinguishing CMV reactivation from CMV diseaseTreatment thresholds and target viral loadsProphylaxis strategies in non-allograft settingsValaciclovir dosing in general hematology populationsHigh-risk patient populationsFirst-Line TherapiesValganciclovir: advantages, disadvantages, and myelosuppressionFoscarnet: indications and monitoring strategiesTreatment-resistant CMVAllogeneic Transplant PatientsHigh-risk populations and timing of reactivationMonitoring protocols post-transplantRandomized Controlled TrialsAURORA Trial: Maribavir vs. ValganciclovirDesign: RCT comparing maribavir to valganciclovir for pre-emptive CMV therapy post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/38036487/]NEJM Letermovir Prophylaxis TrialDesign: Double-blind, placebo-controlled RCT of letermovir prophylaxis post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/29211658/]Emerging Patient PopulationsCMV in lymphoma and myeloma patients receiving CAR T-cell therapy and T-cell engaging bispecific antibodiesMonitoring and prophylaxis strategies for novel immunotherapiesImpact of CMV on post-CAR T mortality-https://pubmed.ncbi.nlm.nih.gov/40203190/

In this episode... Childhood memories. Village tales. Horse and cart. Spy radios. Milkman. Coal man.Sayings from the old days. Kelly's directory and so much more...

Fast food restaurants like Wendy's are experiencing a slowdown in business The fast-food restaurant Wendy's is planning on closing hundreds of locations throughout next year because they continue to see a slowdown in spending from their customers. They said most of their low-income consumers are cutting spending and making fewer trips with smaller purchases at the restaurants. Wendy's increased prices after the pandemic at a higher rate than grocery stores and now other fast-food restaurants have begun to add value menus to keep customers coming back, but Wendy's has held firm and not created any values for their customers. Because of this they have seen their net income decline to $44.3 million from a year ago when it was $50.2 million. Over the past year the stock has declined from around $18 a share down to under $9 a share, which is a decline of 53%. With the reduction in the stock price, the dividend yield is now 6.5% and the company trades at 10 times earnings on a forward basis. This company may be worth looking into as an investment as within in the next 6 to 12 months we could see lower end consumers stabilize.   The affordability index for people buying a home is the worst in 50 years People may be excited about buying a home because mortgage rates are around the lowest they've been in over a year, but the affordability of a home is still far out of reach for many. The reason for this, and we have talked about this for the last few years, is that the increase in the price of homes has far outpaced the increase in people's income. The 50-year average for a price-to-income ratio is around four times, and it reached a low in 1999 of around 3.6 times. But with the rapid increase of homes over the last few years, the price to income ratio has climbed to slightly over five times. Also not helping are the increases in home insurance costs and property taxes. Back in the summer of 2019, when looking at households earning $75,000, nearly 50% of those people could afford to buy a home. Today, when looking at those same households earning $75,000, only 21% would be able to afford a home. Back in 2012, the home affordability index was over 200, but it has now been cut in half to just about 100 with no signs of improving any time soon. I believe it will probably take 3 to 5 years to correct itself. If you look back in history, the affordability index does not change overnight. What will happen is probably incomes will increase slightly over the next 3 to 5 years and maybe the price of homes will either stay the same or decline slightly, which would increase the affordability index. What this means for people buying a home today is you should not have any aspirations of a rapid increase in the value of your home. What caused the problem was during the pandemic mortgage rates dropped to lows not seen in 50 years and that pushed up demand and the prices for homes climbed at a rapid rate. I believe this scenario is extremely unlikely to play out again! The brokerage firm Robinhood looks more like a gambling platform than a brokerage firm Robinhood initially went public at $38 a share in 2023 and the stock then fell to under $10 a share. It has recovered nicely since then as it's now trading around $110 a share. What has caused this shift and the huge increase in the stock price? One big reason is that the company has really allowed major speculation for their investors. Starting off with crypto, they have allowed people to buy coins like BONK, Dogwifhat and Pudgy Penguins. Just when you think there's no way they could come up with anything more speculative, surprise; they have come up with an investment known as prediction markets and event trading. Somehow the regulators have let this slide or maybe since government agencies don't move that quickly, it just has not been addressed yet. It appears for investors on their app that you can predict what the outcome will be of a football game, politics, contracts over economics, even if aliens will exist on earth this year. Chief Brokerage Officer, Steve Quirk, says this is the fastest growing business we have ever had. Robinhood stock trades over 50 times projected earnings and is looking for about $4.5 billion in revenue, which is an increase of 53% over last year. The growth appears to be there for the company, but there is so much speculation and insane crazy things there is no doubt in my mind that in the future many people will lose more money than they ever thought was possible by speculating on crazy things rather than investing into good quality businesses. A fallout in those risky "investments" could hurt Robinhood's reputation, which I believe would be bad for long term growth.    Financial Planning: The Real Cost of Employer Coverage vs. Medicare When reaching age 65, sometimes there is the option to join Medicare or stay with an employer health insurance plan.  This is most common when a spouse retires after age 65 and they have the ability to join their spouse's work plan. When comparing the cost of coverage, there is a key difference in how each affects your tax bill. Premiums paid through payroll for employer-sponsored health insurance are pre-tax, meaning you avoid federal, state, and payroll taxes such as the 6.2% Social Security, 1.45% Medicare, and 1.2% CA SDI tax in California.  This is different from a 401(k) for example where contributions are only pre-tax from federal and state taxes. For someone in the 22% tax bracket, a $500 premium would be around $300 after the tax savings. Medicare premiums on the other hand are paid with after-tax dollars and are only tax-deductible for people who itemize and have total medical expenses exceeding 7.5% of AGI, which means very few retirees actually receive any tax benefit. Additionally, Medicare Part B and D premiums may be elevated due to higher levels of income because of IRMAA. Employer health insurance can vary in coverage and cost so at times Medicare may be a more comprehensive and cost-effective option, but it is necessary to compare the after-tax costs to be sure.   Companies Discussed: Cisco Systems, Inc. (CSCO), The Walt Disney Company (DIS), Spectrum Brands Holdings, Inc. (SPB), Maplebear Inc. (CART)

Prosecutors allege that during a video-conference session with her lawyers at MDC Brooklyn, Maxwell used a large cart loaded with legal documents to block the door of a dedicated conference room, effectively preventing prison staff from entering. The filing states she was permitted to bring the cart into the video‐teleconference (VTC) room for meetings, but then “used that cart to barricade the door to the room” when staff attempted to gain access.In response, Maxwell's legal team denied the barricade claim, arguing the government was “gratuitously casting” her in a negative light to justify stricter limits on her legal material access. Following the incident, prison authorities removed and banned the use of the cart during her meetings, directing that she instead carry her documents by hand and make multiple trips if needed.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Happy Thursday you pop culture junkies!   This week's pod takes a look at the hilarious social media reactions to the rainstorm in Los Angeles. Angelenos really do lose it the moment a single raindrop hits the ground, and the memes did not disappoint. We also dive into the newest gourmet food sensation in New York, Meadow Lane, opened by a social media influencer and quickly becoming the Erewhon of the East Coast.   Plus, we get into the absolute travesty of Apple's latest accessory, the iPhone Pocket, and why the internet is collectively cringing. There are also some wonderfully awkward TikTok trends making the rounds that we can't ignore. And as always, we wrap with what to watch this week — from new releases to comfort binges you'll be obsessed with.   https://popculturemondays.com/2025/11/17/its-raining/

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show

This is a free preview of a paid episode. To hear more, visit meetthemess.substack.comMove over, Meet the Press—it's time to MEET THE MESS!This week on the podcast, Jen and Karyn are back! The House voted to release the Epstein files, but will it actually happen? Meanwhile, Trump delivers a completely bananas speech to McDonald's franchise owners and tells a female reporter, “Quiet, piggy.”Also on deck: a behavioral scientist breaks down what it means when someone does (or doesn't) return their cart. Plus, Kim Kardashian fails the bar exam, the FDA removes the black box warning from menopause hormone therapy, and a flamingo escapes a British zoo and decides to retire on a beach in the south of France. And finally, do you have a preferred font?On Meet the Mess, bestselling authors Jen Lancaster & Karyn Bosnak dive into the messiest news stories and hottest topics of the week to give a fresh and entertaining take on current events and life in general. An extended video version with the “Hot Mess of the Week” is available to paid Substack subscribers. Visit meetthemess.substack.com for more.Meet the Merch:• https://www.etsy.com/shop/MeetTheMessConnect with us on Instagram:• https://www.instagram.com/meetthemesspod• https://www.instagram.com/jennsylvania• https://www.instagram.com/karynbosnakConnect with us on TikTok:• https://www.tiktok.com/@meetthemess• https://www.tiktok.com/@karynbosnak

If you're a leader in game dev who feels stuck, there is a path forward that levels up your leadership and accelerates your team, game, and career. Sign up here to learn more: https://forms.gle/nqRTUvgFrtdYuCbr6 Are you leading a team that has plenty of people but can't seem to get moving? You care deeply about your team and your game, but projects crawl and decisions drag in the. It's almost never just a talent problem. Instead, it's three quiet leadership mistakes that choke momentum. In this episode, you'll learn what those three mistakes are, how they're showing up in your studio, and what you can do instead so you can move faster and see real progress on your game. We break down the mistakes one by one with simple shifts you can start immediately. What You'll Learn: The Velocity Trap: Why any speed you have is "pretend" if your team doesn't share a clear North Star (Vision). The Cart in the Mud: The four specific foundational elements you must have in place to earn the right to scale , and what to do when you realize you've scaled too fast. The Crunch Lie: Why overwork and extended crunch quickly make you slower than if you never crunched at all, and how to operate at a sustainable pace. A Simple Reality Check: How to rate your studio's Vision, Scale, and Workload (1-5) to identify your biggest blocker and immediately focus your leadership energy. GameDeveloper.com Article: https://www.gamedeveloper.com/production/addressing-crunch-the-games-industry-s-worst-practice-2 Connect with us:

Every successful surgery starts with a perfectly assembled case cart. But what happens when the next cart rolling into the OR is missing a critical supply or instrument? This week, we're joined by Courtney Kleeb, Senior Director of Perioperative Surgical Solutions at HealthTrust Performance Group, for a deep dive into what really drives case cart success. From preference card cleanup to fixing inefficient pick paths that send your team zigzagging, Courtney breaks down the real-world strategies that turn incomplete carts into streamlined workflows. Whether you're dealing with multiple departments all touching the same cart or just tired of chasing down missing supplies between cases, this conversation has the practical solutions you need to unite your OR, SPD, and Supply Chain around one goal—delivering excellent patient care! Season 30 of Beyond Clean releases under the 1 Episode = 1 CE delivery model. After finishing this interview, earn your 1 CE credit immediately by passing the short quiz linked here: https://www.flexiquiz.com/SC/N/episode30-07 Visit our CE Credit Hub at https://www.beyondcleanmedia.com/ce-credit-hub to access this quiz and over 350 other free CE credits. #BeyondClean #SterileProcessing #Podcast #Season30 #TrayCommand #CaseCarts #Accuracy #Surgery #SurgicalSupplies #Instruments